Internet-based Affect Focused Psychodynamic Therapy for Neuroticism: a Randomized Controlled Trial

NCT ID: NCT06665321

Last Updated: 2024-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-31

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to investigate if internet delivered affect-focused psychodynamic therapy (IPDT) leads to lowered levels of trait neuroticism compared to a wait-list control condition. The target group is adults (18+) who experience mild to moderate symptoms of anxiety and/or depression. The IPDT treatment consists of 8 modules that the participants will work with for 9 weeks, with therapist support. Participants will be recruited in Sweden with nationwide recruitment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized controlled trial with the aim to investigate if IPDT leads to lowered levels of trait neuroticism. Participants will either be randomized to the treatment which is based on Affect Phobia Therapy or to a wait-list control. Participants will have weekly contact with a therapist who will provide feedback and support.

Primary outcome measure is trait neuroticism (measured on the 24-Item Neuroticism scale of the IPIP-NEO-120). Secondary outcome measures will include measures of anxiety, depression, quality of life, emotion regulation, and defense mechanism adaptiveness. Emotion regulation and short measure of anxiety and depressive symptoms will be collected weekly throughout the treatment period. Pre-treatment measurement, post-treatment measurement, weekly measure, and one-year follow up is planned to be collected through an online survey.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Trait Neuroticism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

After recruitment finished, participants will be randomized to either IPDT treatment or wait-list control condition.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Internet-based psychodynamic therapy

The treatment consist of a 9 week long IPDT intervention based on Affect Phobia Therapy with weekly therapist support.

Group Type EXPERIMENTAL

Internet-based psychodynamic therapy (IPDT)

Intervention Type BEHAVIORAL

The intervention is 9 week long with weekly modules that the participants work with while receiving weekly support from an assigned therapist.

Wait-list control condition

Wait-list control condition, participants have the option to contact the treatment team in case of worsened symptoms.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Internet-based psychodynamic therapy (IPDT)

The intervention is 9 week long with weekly modules that the participants work with while receiving weekly support from an assigned therapist.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Score 5 points or more on either the PHQ-9 or GAD-7
* 18 years or older
* Ability to speak, read and write in Swedish
* Have access to the internet and a smartphone, computer or other device

Exclusion Criteria

* Severe psychiatric or somatic illness that makes participation difficult or impossible
* Ongoing addiction
* Acute suicidality
* Other ongoing psychological treatment
* Recent (within the latest month) changes in the dose of psychotropic medication or planned change of dose during the treatment weeks
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Linkoeping University

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gerhard Andersson

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gerhard Andersson, PhD

Role: PRINCIPAL_INVESTIGATOR

Linkoeping University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Behavioral Sciences and Learning

Linköping, Östergörland, Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gerhard Andersson, PhD

Role: CONTACT

+46-13285840

Tomas Lindegaard, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gerhard Andersson, PhD

Role: primary

+46-13285840

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LINNEA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ICBT for Depression in Older Adults
NCT05269524 COMPLETED NA
ICBT for Antenatal Depression
NCT02366429 COMPLETED NA